[go: up one dir, main page]

WO2008131575A3 - Anti-alk antibodies suitable for treating metastatic cancers or tumors - Google Patents

Anti-alk antibodies suitable for treating metastatic cancers or tumors Download PDF

Info

Publication number
WO2008131575A3
WO2008131575A3 PCT/CH2008/000193 CH2008000193W WO2008131575A3 WO 2008131575 A3 WO2008131575 A3 WO 2008131575A3 CH 2008000193 W CH2008000193 W CH 2008000193W WO 2008131575 A3 WO2008131575 A3 WO 2008131575A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumors
metastatic cancers
antibodies suitable
treating metastatic
alk antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CH2008/000193
Other languages
French (fr)
Other versions
WO2008131575A2 (en
Inventor
Der Maur Adrian Auf
Alcide Barberis
Peter Lichtlen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esbatech a Novartis Co LLC
Original Assignee
Esbatech AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esbatech AG filed Critical Esbatech AG
Publication of WO2008131575A2 publication Critical patent/WO2008131575A2/en
Publication of WO2008131575A3 publication Critical patent/WO2008131575A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention concerns an antibody specific for human ALK (Anaplastic Lymphoma Kinase), in particular a scFv, a nucleic acid sequence encoding it, its production and its use as a pharmaceutical or for diagnostic purposes. Said antibody is suitable for the local treatment of tumors, for example, metastatic cancer or tumors, in particular, glioblastoma.
PCT/CH2008/000193 2007-04-27 2008-04-28 Anti-alk antibodies suitable for treating metastatic cancers or tumors Ceased WO2008131575A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92681007P 2007-04-27 2007-04-27
US60/926,810 2007-04-27

Publications (2)

Publication Number Publication Date
WO2008131575A2 WO2008131575A2 (en) 2008-11-06
WO2008131575A3 true WO2008131575A3 (en) 2009-01-29

Family

ID=39926146

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CH2008/000193 Ceased WO2008131575A2 (en) 2007-04-27 2008-04-28 Anti-alk antibodies suitable for treating metastatic cancers or tumors

Country Status (1)

Country Link
WO (1) WO2008131575A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103857700A (en) 2011-08-26 2014-06-11 梅里麦克制药股份有限公司 Tandem FC bispecific antibodies
US9458245B2 (en) 2013-03-06 2016-10-04 Merrimack Pharmaceuticals, Inc. ANTI-C-MET tandem Fc bispecific antibodies
US20160017024A1 (en) * 2013-03-12 2016-01-21 Five Prime Therapeutics, Inc. Fam150a, fam150b, and fam150 antagonists and uses thereof
US11091559B2 (en) 2015-08-27 2021-08-17 Celldex Therapeutics, Inc. Anti-ALK antibodies and methods for use thereof
US20240262917A1 (en) * 2021-05-06 2024-08-08 Dana-Farber Cancer Institute, Inc. Antibodies against alk and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097697A2 (en) * 2002-05-22 2003-11-27 Esbatech Ag Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
WO2007059300A2 (en) * 2005-11-15 2007-05-24 Medimmune, Inc. Anti-alk antagonist and agonist antibodies and uses thereof
WO2007124610A1 (en) * 2006-04-28 2007-11-08 Esbatech Ag Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097697A2 (en) * 2002-05-22 2003-11-27 Esbatech Ag Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same
WO2007059300A2 (en) * 2005-11-15 2007-05-24 Medimmune, Inc. Anti-alk antagonist and agonist antibodies and uses thereof
WO2007124610A1 (en) * 2006-04-28 2007-11-08 Esbatech Ag Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MOOG-LUTZ CHRISTEL ET AL: "Activation and inhibition of anaplastic lymphoma kinase receptor tyrosine kinase by monoclonal antibodies and absence of agonist activity of pleiotrophin", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,; US, vol. 280, no. 28, 1 July 2005 (2005-07-01), pages 26039 - 26048, XP002424604, ISSN: 0021-9258 *
MOTEGI AKIRA ET AL: "ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth", JOURNAL OF CELL SCIENCE, CAMBRIDGE UNIVERSITY PRESS, LONDON, GB, vol. 117, no. 15, 1 July 2004 (2004-07-01), pages 3319 - 3329, XP002424605, ISSN: 0021-9533 *
POWERS CIARAN ET AL: "Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 16, 19 April 2002 (2002-04-19), pages 14153 - 14158, XP002503924, ISSN: 0021-9258 *
STOICA GERALD E ET AL: "Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,; US, vol. 277, no. 39, 27 September 2002 (2002-09-27), pages 35990 - 35998, XP002290577, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2008131575A2 (en) 2008-11-06

Similar Documents

Publication Publication Date Title
WO2007109321A3 (en) Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
PH12018550164A1 (en) Bcma binding molecules and methods of use thereof
WO2008066691A3 (en) Tes7 and antibodies that bind thereto
ZA200702973B (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for CDK2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
WO2009032949A3 (en) High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
WO2008140493A3 (en) Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof
CY1118693T1 (en) ANTI-ACTIVE AIDS AND USE OF THESE
WO2005097832A3 (en) Humanized anti-tgf-beta antibodies
NZ704295A (en) Compositions and methods for the treatment of infections and tumors
WO2007084181A3 (en) Bispecific single chain fv antibody molecules and methods of use thereof
WO2007013950A3 (en) Combination therapy of her expressing tumors
WO2004058171A3 (en) Antibodies against gpr64 and uses thereof
WO2007067992A3 (en) Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
WO2007067991A3 (en) Human monoclonal antibodies to o8e
AU2006226897B2 (en) Combinations for the treatment of cancer comprising anti-EGFR antibody and VEGFR inhibitors
WO2012177595A9 (en) Compositions and methods for the therapy and diagnosis of cancer
BRPI0916138A2 (en) "method of treating a locally diagnosed breast cancer subject, kit for treating metastatic breast cancer in a human subject, use of an antivegf antibody in the manufacture of a medicament for treating locally relapsed or metastatic breast cancer in a subject, and antibody". anti-vegf for use in a method of treating locally relapsed or metastatic breast cancer in a subject "
WO2006084075A3 (en) Adam-9 modulators
WO2011015333A3 (en) Targeting of bone marrow neovasculature
WO2008151819A3 (en) Treatment of tumors using specific anti-l1 antibody
WO2007141280A3 (en) Proteins
WO2007135546A3 (en) TREATMENT OF CANCER WITH ANTI-IL-1α ANTIBODIES
WO2009004484A3 (en) Trim24 (tifla) as p53 modulator and cancer target
WO2006084078A3 (en) Jam-3 and antibodies that bind thereto
WO2008136848A3 (en) Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08733819

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08733819

Country of ref document: EP

Kind code of ref document: A2